Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study ID
- NCT06706674
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Irritability Associated With Autism Spectrum Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- Lumateperone high dose — DRUGLumateperone administered orally once daily
- Lumateperone low dose — DRUGLumateperone administered orally once daily
- Placebo — DRUGMatching Placebo administered orally once daily
Study Details
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Key Dates
- First listed
- Nov 26, 2024
- Start date
- Dec 6, 2024
- Status verified
- Jul 2026
- Primary completion
- Jun 21, 2027
- Completion
- Jun 21, 2027
Study Design
- Enrollment
- 160 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Lumateperone high doseLumateperone 42 mg for patients ages 13-17 years old
- Experimental: Lumateperone low doseLumateperone 21 mg for patients ages 13-17 years old
- Placebo Comparator: PlaceboPlacebo
Primary Outcome Measure
Aberrant Behavior Checklist - Irritability (ABC-I) [ Time Frame: Week 6 ]
Central Contacts
- ITI Clinical Trials646 440-9333
Locations (38)
Find similar trials in Little Rock, AR
Related Studies
- Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric PatientsPHASE3 · Recruiting · Intra-Cellular Therapies, Inc. · Dothan, Alabama
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With AutismPHASE3 · Not Yet Recruiting · Bristol-Myers Squibb · Dothan, Alabama
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum DisorderPHASE3 · Not Yet Recruiting · Bristol-Myers Squibb · Phoenix, Arizona